JP2018527924A - Ｍｒｋａポリペプチド、抗体、およびその使用 - Google Patents

Ｍｒｋａポリペプチド、抗体、およびその使用 Download PDF

Info

Publication number
JP2018527924A
JP2018527924A JP2018509904A JP2018509904A JP2018527924A JP 2018527924 A JP2018527924 A JP 2018527924A JP 2018509904 A JP2018509904 A JP 2018509904A JP 2018509904 A JP2018509904 A JP 2018509904A JP 2018527924 A JP2018527924 A JP 2018527924A
Authority
JP
Japan
Prior art keywords
mrka
seq
antibody
binding protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018509904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527924A5 (https=
Inventor
ワン，クン
ラジャン，サラヴァナン
チャン，チェウ−シュン
トンプソン，ジェニー ヘイドブリンク
トンプソン，ジェニー ヘイドブリンク
リン，フン−ユ
ケンダル ストーヴァー，チャールズ
ケンダル ストーヴァー，チャールズ
ペンニニ，メグハン
ダルアクア，ウィリアム
エス． チョウダリー，パーサ
エス． チョウダリー，パーサ
シャオ，シャオドン
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2018527924A publication Critical patent/JP2018527924A/ja
Publication of JP2018527924A5 publication Critical patent/JP2018527924A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018509904A 2015-08-24 2016-08-23 Ｍｒｋａポリペプチド、抗体、およびその使用 Pending JP2018527924A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US62/208,975 2015-08-24
US201562238828P 2015-10-08 2015-10-08
US62/238,828 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (2)

Publication Number Publication Date
JP2018527924A true JP2018527924A (ja) 2018-09-27
JP2018527924A5 JP2018527924A5 (https=) 2019-10-03

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018509904A Pending JP2018527924A (ja) 2015-08-24 2016-08-23 Ｍｒｋａポリペプチド、抗体、およびその使用

Country Status (16)

Country Link
US (2) US20170073397A1 (https=)
EP (1) EP3341004A4 (https=)
JP (1) JP2018527924A (https=)
KR (1) KR20180042300A (https=)
CN (1) CN107921086A (https=)
AU (1) AU2016313653A1 (https=)
BR (1) BR112018003252A2 (https=)
CA (1) CA2995387A1 (https=)
CL (1) CL2018000357A1 (https=)
CO (1) CO2018001985A2 (https=)
HK (1) HK1252350A1 (https=)
IL (1) IL257434A (https=)
MX (1) MX2018001964A (https=)
RU (1) RU2018107056A (https=)
TW (1) TW201718626A (https=)
WO (1) WO2017035154A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
US11117956B2 (en) 2016-10-19 2021-09-14 Medimmune, Llc Anti-O1 antibodies and uses thereof
WO2018237221A1 (en) * 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation IMMUNOGENIC COMPOSITIONS
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027116A1 (en) * 2009-09-04 2011-03-10 London School Of Hygiene And Tropical Medicine Protein glycosylation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU7470300A (en) * 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CA2541360A1 (en) * 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2489673A3 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US20140011691A1 (en) * 2010-10-26 2014-01-09 Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and on Behalf of Az. Morphology and protein specific reagents as diagnostics for neurodegenerative diseases
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027116A1 (en) * 2009-09-04 2011-03-10 London School Of Hygiene And Tropical Medicine Protein glycosylation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIA-HAN CHAN: "Identification of Protein Domains on Major Pilin MrkA That Affects the Mechanical Properties of Kleb", LANGMUIR, vol. 28, JPN6020035324, 2012, pages 7428 - 7435, XP055566231, ISSN: 0004348448, DOI: 10.1021/la300224w *
RASMYIA ABED ABU-RESHA, INTRODUCTION PROPHYLACTIC ROLE OF ANTI-FIMBRIAE TYPE 3 FROM BIOFILM FORMATION BY KLEBSIELLA PNEUMONI, JPN6020035320, 17 May 2014 (2014-05-17), pages Abstract, ISSN: 0004348447 *
YING-JUNG HUANG: "MrkF is a component of type 3 fimbriae in Klebsiella pneumoniae", RESEARCH IN MICROBIOLOGY, vol. 160, JPN6020035322, 2009, pages 71 - 79, XP025771449, ISSN: 0004348449, DOI: 10.1016/j.resmic.2008.10.009 *

Also Published As

Publication number Publication date
US20190062411A1 (en) 2019-02-28
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02
EP3341004A1 (en) 2018-07-04
CO2018001985A2 (es) 2018-11-22
CL2018000357A1 (es) 2018-07-20
MX2018001964A (es) 2018-06-19
TW201718626A (zh) 2017-06-01
AU2016313653A1 (en) 2018-04-12
US20170073397A1 (en) 2017-03-16
HK1252350A1 (zh) 2019-05-24
CN107921086A (zh) 2018-04-17
EP3341004A4 (en) 2019-05-15
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
BR112018003252A2 (pt) 2018-09-25
WO2017035154A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
US20240383969A1 (en) Anti-o1 antibodies and uses thereof
US12312397B2 (en) Anti-O2 antibodies and uses thereof
US20190062411A1 (en) Mrka polypeptides, antibodies, and uses thereof
CN112672788B (zh) 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
JP6473746B2 (ja) 交差反応性黄色ブドウ球菌抗体配列
KR20170136637A (ko) 항-스타필로코커스 아우레우스 항체 배합 제제
CA3117945A1 (en) Anti-cfae antibodies and methods of use
KR102955585B1 (ko) 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체
HK1248576A1 (en) Mrka polypeptides, antibodies, and uses thereof
HK40009426A (en) Anti-o1 antibodies and uses thereof
HK40007861A (zh) 抗o2抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210511